## **Bertrand Audoin**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7114260/publications.pdf

Version: 2024-02-01

78 papers 4,332 citations

36 h-index 63 g-index

81 all docs

81 docs citations

81 times ranked 4047 citing authors

#	Article	IF	CITATIONS
1	Hypogammaglobulinemia and Infections in Patients With Multiple Sclerosis Treated With Rituximab. Neurology: Neuroimmunology and NeuroInflammation, 2022, 9, .	3.1	36
2	Interleukin-6 Receptor Blockade in Treatment-Refractory MOG-lgG–Associated Disease and Neuromyelitis Optica Spectrum Disorders. Neurology: Neuroimmunology and NeuroInflammation, 2022, 9, .	3.1	64
3	Pure Relapsing Short Myelitis. Neurology: Neuroimmunology and NeuroInflammation, 2022, 9, .	3.1	5
4	Grey-matter sodium concentration as an individual marker of multiple sclerosis severity. Multiple Sclerosis Journal, 2022, 28, 1903-1912.	1.4	2
5	Fatal underhanded chronic enterovirus infection associated with anti-CD20 monotherapy for central nervous system demyelinating disease. Multiple Sclerosis Journal, 2021, 27, 320-323.	1.4	8
6	Maintenance of natalizumab during the first trimester of pregnancy in active multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 712-718.	1.4	13
7	Comparison of rituximab originator (MabThera <sup><math>\hat{A}^{\otimes}</math></sup> ) to biosimilar (Truxima <sup><math>\hat{A}^{\otimes}</math></sup> ) in patients with multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 585-592.	1.4	10
8	MRI characteristics of MOG-Ab associated disease in adults: An update. Revue Neurologique, 2021, 177, 39-50.	0.6	15
9	Clinical Features and Risk of Relapse in Children and Adults with Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease. Annals of Neurology, 2021, 89, 30-41.	2.8	123
10	Mind the gap: from neurons to networks to outcomes in multiple sclerosis. Nature Reviews Neurology, 2021, 17, 173-184.	4.9	46
11	The longâ€ŧerm outcome of MOGAD: An observational national cohort study of 61 patients. European Journal of Neurology, 2021, 28, 1659-1664.	1.7	26
12	Rituximab-Induced Hypogammaglobulinemia and Infections in AQP4 and MOG Antibody–Associated Diseases. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	3.1	26
13	Delayed access to conscious processing in multiple sclerosis: Reduced cortical activation and impaired structural connectivity. Human Brain Mapping, 2021, 42, 3379-3395.	1.9	1
14	TNF- $\hat{l}\pm$ inhibitors used as steroid-sparing maintenance monotherapy in parenchymal CNS sarcoidosis. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 890-896.	0.9	8
15	A metaâ€nalysis comparing firstâ€ine immunosuppressants in neuromyelitis optica. Annals of Clinical and Translational Neurology, 2021, 8, 2025-2037.	1.7	20
16	Determining the best window for BNT162b2 mRNA vaccination for SARS-CoV-2 in patients with multiple sclerosis receiving anti-CD20 therapy. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2021, 7, 205521732110621.	0.5	6
17	Author Response: Evaluation of Efficacy and Tolerability of First-Line Therapies in NMOSD. Neurology, 2021, 96, 295-296.	1.5	О
18	Longitudinal study of functional brain network reorganization in clinically isolated syndrome. Multiple Sclerosis Journal, 2020, 26, 188-200.	1.4	17

#	Article	IF	CITATIONS
19	Frequency and characteristics of short versus longitudinally extensive myelitis in adults with MOG antibodies: A retrospective multicentric study. Multiple Sclerosis Journal, 2020, 26, 936-944.	1.4	37
20	Comparison of the Response to Rituximab between Myelin Oligodendrocyte Glycoprotein and Aquaporinâ€4 Antibody Diseases. Annals of Neurology, 2020, 87, 256-266.	2.8	100
21	Aerobic Exercise Induces Functional and Structural Reorganization of CNS Networks in Multiple Sclerosis: A Randomized Controlled Trial. Frontiers in Human Neuroscience, 2020, 14, 255.	1.0	10
22	Sensitivity of the Inhomogeneous Magnetization Transfer Imaging Technique to Spinal Cord Damage in Multiple Sclerosis. American Journal of Neuroradiology, 2020, 41, 929-937.	1.2	16
23	Treatment of MOG-IgG-associated disorder with rituximab: An international study of 121 patients. Multiple Sclerosis and Related Disorders, 2020, 44, 102251.	0.9	110
24	Evaluation of efficacy and tolerability of first-line therapies in NMOSD. Neurology, 2020, 94, e1645-e1656.	1.5	66
25	Extending rituximab dosing intervals in patients with MS during the COVID-19 pandemic and beyond?. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	3.1	49
26	Improved Cervical Cord Lesion Detection with 3D-MP2RAGE Sequence in Patients with Multiple Sclerosis. American Journal of Neuroradiology, 2020, 41, 1131-1134.	1.2	7
27	Brain MRI features and scoring of leukodystrophy in adult-onset Krabbe disease. Neurology, 2019, 93, e647-e652.	1.5	25
28	Evaluation of treatment response in adults with relapsing MOG-Ab-associated disease. Journal of Neuroinflammation, 2019, 16, 134.	3.1	115
29	Spatial distribution of multiple sclerosis lesions in the cervical spinal cord. Brain, 2019, 142, 633-646.	3.7	75
30	Usefulness of MOG-antibody titres at first episode to predict the future clinical course in adults. Journal of Neurology, 2019, 266, 806-815.	1.8	47
31	Automatic segmentation of the spinal cord and intramedullary multiple sclerosis lesions with convolutional neural networks. Neurolmage, 2019, 184, 901-915.	2.1	163
32	Metabolic counterparts of sodium accumulation in multiple sclerosis: A whole brain <sup>23</sup> Na-MRI and fast <sup>1</sup> H-MRSI study. Multiple Sclerosis Journal, 2019, 25, 39-47.	1.4	14
33	Efficacy of rituximab in refractory RRMS. Multiple Sclerosis Journal, 2019, 25, 828-836.	1.4	28
34	Effects of cognitive impairment on prosodic parameters of speech production planning in multiple sclerosis. Journal of Neuropsychology, 2019, 13, 22-45.	0.6	24
35	Recommendations for the use of Rituximab in neuromyelitis optica spectrum disorders. Revue Neurologique, 2018, 174, 255-264.	0.6	47
36	Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults. Neurology, 2018, 90, e1858-e1869.	1.5	401

3

#	Article	IF	Citations
37	How much progress has there been in the second-line treatment of multiple sclerosis: A 2017 update. Revue Neurologique, 2018, 174, 429-440.	0.6	6
38	Monitoring CD27 + memory B-cells in neuromyelitis optica spectrum disorders patients treated with rituximab: Results from a bicentric study. Journal of the Neurological Sciences, 2017, 373, 335-338.	0.3	58
39	Increased total sodium concentration in gray matter better explains cognition than atrophy in MS. Neurology, 2017, 88, 289-295.	1.5	40
40	Effectiveness of mycophenolate mofetil as first-line therapy in AQP4-lgG, MOG-lgG, and seronegative neuromyelitis optica spectrum disorders. Multiple Sclerosis Journal, 2017, 23, 1377-1384.	1.4	89
41	Hypoperfusion of the thalamus is associated with disability in relapsing remitting multiple sclerosis. Journal of Neuroradiology, 2017, 44, 158-164.	0.6	34
42	New brain lesions with no impact on physical disability can impact cognition in early multiple sclerosis: A ten-year longitudinal study. PLoS ONE, 2017, 12, e0184650.	1.1	15
43	Metabolic voxelâ€based analysis of the complete human brain using fast 3Dâ€MRSI: Proof of concept in multiple sclerosis. Journal of Magnetic Resonance Imaging, 2016, 44, 411-419.	1.9	31
44	Normalisation of brain spectroscopy findings in Niemann–Pick disease type C patients treated with miglustat. Journal of Neurology, 2016, 263, 927-936.	1.8	20
45	Suivi IRM des patients SEPÂ: pourquoiÂ?. Pratique Neurologique - FMC, 2016, 7, 149-152.	0.1	0
46	Depletion of brain functional connectivity enhancement leads to disability progression in multiple sclerosis: A longitudinal resting-state fMRI study. Multiple Sclerosis Journal, 2016, 22, 1695-1708.	1.4	54
47	Longitudinal fMRI studies: Exploring brain plasticity and repair in MS. Multiple Sclerosis Journal, 2016, 22, 269-278.	1.4	37
48	Efficacy of rituximab in refractory neuromyelitis optica. Multiple Sclerosis Journal, 2016, 22, 955-959.	1.4	55
49	Brain functional plasticity at rest and during action in multiple sclerosis patients. Journal of Clinical Neuroscience, 2015, 22, 1438-1443.	0.8	10
50	Rituximab as first-line therapy in neuromyelitis optica: efficiency and tolerability. Journal of Neurology, 2015, 262, 2329-2335.	1.8	86
51	Voxelwise analysis of conventional magnetic resonance imaging to predict future disability in early relapsing–remitting multiple sclerosis. Multiple Sclerosis Journal, 2012, 18, 1585-1591.	1.4	11
52	Assessing brain connectivity at rest is clinically relevant in early multiple sclerosis. Multiple Sclerosis Journal, 2012, 18, 1251-1258.	1.4	133
53	In vivo quantification of brain injury in adult Niemann–Pick Disease Type C. Molecular Genetics and Metabolism, 2011, 103, 138-141.	0.5	18
54	Prevalence of Grey Matter Pathology in Early Multiple Sclerosis Assessed by Magnetization Transfer Ratio Imaging. PLoS ONE, 2011, 6, e24969.	1.1	45

#	Article	IF	Citations
55	Occurrence of neuronal dysfunction during the first 5Âyears of multiple sclerosis is associated with cognitive deterioration. Journal of Neurology, 2011, 258, 811-819.	1.8	17
56	Motor cortical reorganization is present after a single attack of multiple sclerosis devoid of cortico-spinal dysfunction. Magnetic Resonance Materials in Physics, Biology, and Medicine, 2011, 24, 77-84.	1.1	11
57	Advanced magnetic resonance imaging techniques to better understand multiple sclerosis. Biophysical Reviews, 2010, 2, 83-90.	1.5	3
58	Individual voxelâ€based analysis of brain magnetization transfer maps shows great variability of gray matter injury in the first stage of multiple sclerosis. Journal of Magnetic Resonance Imaging, 2010, 32, 424-428.	1.9	14
59	Atrophy mainly affects the limbic system and the deep grey matter at the first stage of multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, 690-695.	0.9	140
60	Processus conscients et non conscients. , 2010, , 123-127.		0
61	Méthodes de RMN avancées et explorations intégrées. , 2010, , 165-175.		0
62	White matter damage impairs access to consciousness in multiple sclerosis. NeuroImage, 2009, 44, 590-599.	2.1	37
63	Efficiency of cognitive control recruitment in the very early stage of multiple sclerosis: a one-year fMRI follow-up study. Multiple Sclerosis Journal, 2008, 14, 786-792.	1.4	48
64	Voxel-based analysis of grey matter magnetization transfer ratio maps in early relapsing remitting multiple sclerosis. Multiple Sclerosis Journal, 2007, 13, 483-489.	1.4	44
65	Early cognitive impairment in patients with clinically isolated syndrome suggestive of multiple sclerosis. Multiple Sclerosis Journal, 2007, 13, 124-127.	1.4	223
66	Onset and underpinnings of white matter atrophy at the very early stage of multiple sclerosis - a two-year longitudinal MRI/MRSI study of corpus callosum. Multiple Sclerosis Journal, 2007, 13, 41-51.	1.4	50
67	Structure of WM bundles constituting the working memory system in early multiple sclerosis: A quantitative DTI tractography study. NeuroImage, 2007, 36, 1324-1330.	2.1	98
68	Localized grey matter damage in early primary progressive multiple sclerosis contributes to disability. NeuroImage, 2007, 37, 253-261.	2.1	99
69	Intact subliminal processing and delayed conscious access in multiple sclerosis. Neuropsychologia, 2007, 45, 2683-2691.	0.7	26
70	Structural and functional surrogates of cognitive impairment at the very early stage of multiple sclerosis. Journal of the Neurological Sciences, 2006, 245, 161-167.	0.3	49
71	Localization of grey matter atrophy in early RRMS. Journal of Neurology, 2006, 253, 1495-1501.	1.8	102
72	Selective magnetization transfer ratio decrease in the visual cortex following optic neuritis. Brain, 2006, 129, 1031-1039.	3.7	88

#	Article	IF	CITATIONS
73	Altered Functional Connectivity Related to White Matter Changes inside the Working Memory Network at the Very Early Stage of MS. Journal of Cerebral Blood Flow and Metabolism, 2005, 25, 1245-1253.	2.4	101
74	Magnetic resonance study of the influence of tissue damage and cortical reorganization on PASAT performance at the earliest stage of multiple sclerosis. Human Brain Mapping, 2005, 24, 216-228.	1.9	167
75	Modulation of effective connectivity inside the working memory network in patients at the earliest stage of multiple sclerosis. NeuroImage, 2005, 24, 533-538.	2.1	128
76	Voxel-based analysis of MTR images: A method to locate gray matter abnormalities in patients at the earliest stage of multiple sclerosis. Journal of Magnetic Resonance Imaging, 2004, 20, 765-771.	1.9	85
77	Compensatory cortical activation observed by fMRI during a cognitive task at the earliest stage of multiple sclerosis. Human Brain Mapping, 2003, 20, 51-58.	1.9	237
78	MRI/MRS of corpus callosum in patients with clinically isolated syndrome suggestive of multiple sclerosis. Multiple Sclerosis Journal, 2003, 9, 554-565.	1.4	56